Penn Medicine Provider
Radiation Oncology
Catherine S. Kim, MD
Accepting new patients
Sees patients age 18 and up
Penn Medicine | Virtua Radiation Oncology - Voorhees
View 1 additional location

About me

  • Medical Director, Penn Medicine Virtua Moorestown, Radiation Oncology
  • Medical Director, Penn Medicine Virtua Voorhees, Radiation Oncology
  • Regional Network Medical Director, Radiation Oncology

Dr. Kim was recognized in Philadelphia magazine's Top Doctor in Cancer Care issues, 2020-2021 and in Philadelphia magazine's annual Top Doc issues, 2020-2024.  She has also been recognized in SJ Magazine's annual Top Doc issues, 2011-2019 and Top Female Doc in 2024.

In addition to Penn Medicine hospital privileges, Dr. Kim also has privileges at Virtua Voorhees Hospital, a Penn Medicine Strategic Alliance partner.

Education and training

  • Medical School: Jefferson Medical College
  • Residency: Mount Sinai Morningside
  • Residency: Thomas Jefferson University Hospital

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Kim is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

My research

Kim CS, Jeter MD Radiation Therapy, Early Stage Non-Small Cell Lung Cancer , www.statpearls.com (Academic eLearning Management System): 2017


Kim CS, Algan O Radiation Therapy, Early Stage Breast Cancer , www.statpearls.com (Academic eLearning Management System): 2017


Amsbaugh M, Kim CS Brain Metastases , www.statpearls.com (Academic eLearning Management System): 2016


Kim Catherine S, Werner-Wasik Maria Images in clinical medicine. Lymphadenopathy. , N Engl J Med, 359(15): 2008,1602


Kim CS, Anne PR, Mitchell EP, Palazzo J, Pequignot E, Fishel R, Goldstein SD, Isenberg GA, Curran W Impact of Pretreatment Tumor Size and Lymph Nodes on Pathologic Complete Response and Survival in a Prospective Trial of Chemoradiation for Locally Advanced Local Rectal Cancer , Int J Radiat Oncol Biol Phys , 63(1): 2005,S164-S165


Kim CS, Anne PR, Mitchell EP, Palazzo J, Pequignot E, Fishel R, Goldstein SD, Isenberg GA, Curran W Tumor size as a predictor of pathologic complete response (pCR) and survival in a prospective trial of chemoradiation for locally advanced rectal cancer , Proc Am Soc Clin Onco, 23(16S): 2005


Kim CS, Gumbs AA, Komarnicky L, Carter D, Hutter R, Palazzo JP, McCure PA, Goodman R, Haffty BG, Rebbeck TR, Weber BL, Turner BC Predicted Gremline BRCA/IBRCA2 Mutations and Second Primary Ipsilateral Breast Cancers in Young Women with Pure Ductal Carinoma in-situ Treated with Breast Conserving Therapy , Int J Radiat Oncol Biol Phys, 48(3, Supplement 1): 2000,142-143